OptumRx has partnered with CoverMyMeds to receive prior authorization requests, saving you time and often delivering real-time determinations.
Visit go.covermymeds.com/OptumRx to begin using this free service.
Please note: All information below is required to process this request.
Mon-Fri: 5am to 10pm Pacific / Sat: 6am to 3pm Pacific

Sutent® Prior Authorization Request Form (Page 1 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required)

Member Name:		
Insurance ID#:		
Date of Birth:		
Street Address:		
City:	State:	Zip:
Phone:		

Provider Information (required)

Provider Name:		
NPI#:	Specialty:	
Office Phone:		
Office Fax:		
Office Street Address:		
City:	State:	Zip:

Medication Information (required)

Medication Name:	Strength:	Dosage Form:
❑ Check if requesting **brand**	Directions for Use:	
❑ Check if request is for **continuation of therapy**		

Clinical Information (required)

Select the diagnosis below:

- ❑ Gastrointestinal stromal tumor (GIST)
- ❑ Islet cell tumors
- ❑ Pancreatic neuroendocrine tumors (pNET)
- ❑ Renal cell carcinoma (RCC)
- ❑ Other diagnosis: _____ ICD-10 Code(s): _____

Clinical Information:

Is this request for continuation of prior Sutent therapy? ❑ **Yes** ❑ **No**
Has the patient used Sutent within the past 120 days? ❑ **Yes** ❑ **No**
Select if Sutent is prescribed by or in consultation with one of the following specialists:

- ❑ Oncologist
- ❑ Neuro-oncologist

For gastrointestinal stromal tumor (GIST), also answer the following:

Has the patient had trial and failure, contraindication, or intolerance to imatinib mesylate (generic Gleevec)? ❑ **Yes** ❑ **No**
Has the patient experienced disease progression on, or contraindication or intolerance to Gleevec (imatinib)? ❑ **Yes** ❑ **No**

For pancreatic neuroendocrine tumors (pNET), also answer the following:

Does the patient have progressive, well-differentiated pNET? ❑ **Yes** ❑ **No**
Does the patient have unresectable disease? ❑ **Yes** ❑ **No**
Does the patient have locally advanced disease? ❑ **Yes** ❑ **No**
Does the patient have metastatic disease? ❑ **Yes** ❑ **No**

For renal cell carcinoma (RCC), also answer the following:

Select if the following applies to the patient's disease:

- ❑ Advanced
- ❑ Metastatic (stage IV disease)
- ❑ Medically or surgically unresectable tumor
- ❑ Relapsed

Will Sutent be used as adjuvant therapy? ❑ **Yes** ❑ **No**
Is the patient at high risk of recurrent RCC following nephrectomy? ❑ **Yes** ❑ **No**

Sutent® Prior Authorization Request Form (Page 2 of 2)

DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Quantity Limit:

What is the quantity requested per DAY? _____

What is the reason for exceeding the plan limitations?

- ❑ Titration or loading-dose purposes
- ❑ Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- ❑ Requested strength/dose is not commercially available
- ❑ There is a medically necessary justification why the patient cannot use a higher commercially available strength to achieve the same dosage and remain within the same dosing frequency. **Please specify**: _____
- ❑ Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: This request may be denied unless all required information is received.
If the patient is not able to meet the above standard prior authorization requirements, please call 1-800-711-4555.
For urgent or expedited requests please call 1-800-711-4555.
This form may be used for non-urgent requests and faxed to 1-800-527-0531.